Nonpharmacologic and Non-opioid Pharmacologic Therapies for Acute and Chronic Pain Management
In this activity, faculty will review many options of nonpharmacologic approaches as well as non-opioid pharmacologic approaches to pain management. Published guidelines for the management of painful chronic conditions such as low back pain and osteoarthritis include recommendations for nonpharmacologic approaches as well as non-opioid pharmacologic approaches. In this activity, 2 experts review recent guideline recommendations from the American College of Physicians, the American College of Rheumatology, US Veterans Affairs and Department of Defense, and the Osteoarthritis Research Society International along with the evidence supporting these recommendations.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Professor of Anesthesiology and Medicine
The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Charles E. Argoff, MD: Advisory Board for Amgen, BioDelivery Sciences International, Inc., Clexio Biosciences, Nevro, Neumentum, Regeneron Pharmaceuticals, SK Life Sciences, Teva Pharmaceuticals, and Tremeau Pharmaceuticals, Inc., and Vertex. Consulting for EnZen Therapeutics, Opioid PMR Consortium, and XGene Pharma. Contracted Research for AbbVie, Allergan, Amgen, Lilly, Lundbeck, and Teva. Services Provided for Promotional Purposes for Collegium. Speaker’s Bureau for AbbVie, Amgen, Biohaven, Lilly, Nevro, Redhill Pharma, and Teva.
Oscar A. de Leon-Casasola, MD: Advisory Board for Esteve Pharma, Heron Therapeutics, Medtronic, Tremeau Pharma.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This activity is approved for 0.50 contact hour of continuing education, which includes 0.25 hours of pharmacology.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity may satisfy topic-based CME/CE requirements for licensure. Please check with your state licensing board for their specific requirements and print this page as documentation as might be needed.
Opioid Analgesic REMS Program Companies
Miller Medical Communications, LLC
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.